Durect Company Profile

16:30 EDT 22nd September 2017 | BioPortfolio

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER™ Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR™ sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR™ transdermal patch technology, the DURIN™ Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners. DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways: To internally develop promising products based on our technologies To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules.


2 Results Way
United States of America


Phone: 408.777.1417
Fax: 408 777 3577

News Articles [42 Associated News Articles listed on BioPortfolio]

Sandoz buys into Durect's long-acting painkiller

Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US. Durect's Posimir is a depot formu...

Durect rockets on news of $293 million deal for Posimir

US biotech Durect saw its share leap 43.75% to $1.15 in pre-market trading after it announced a commercialization…

Sandoz licenses US rights to Durect's Posimir analgesic for up to $293mm

Novartis AG's Sandoz International GMBH licensed exclusive US development and marketing rights to Durect Corp.'s local post-operative pain candidate Posimir, an erodible depot formulation of the nonop...

Durect and Sandoz sign $293m deal to commercialise Posimir in US

Durect has signed a development and commercialisation agreement with Sandoz, a division of Novartis, to develop and market Posimir (Saber-Bupivacaine) in the US.

Novartis’ Sandoz, Durect sign $293m deal for pain killer Posimir

Biopharmaceutical firm Durect has entered into a development and commercialization agreement with Novartis subsidiary Sandoz for Posimir (Saber-Bupivacaine) in the US.

Durect concludes enrolment in PERSIST trial of non-opioid analgesic

US-based biopharmaceutical company Durect has concluded patient enrolment in its Phase III PERSIST clinical trial of Posimir (Saber-Bupivacaine) for pain relief following surgery.

Sandoz, Durect Ink Up to $293M U.S. Deal for Long-Acting Non-Opioid Pain Drug

Sandoz is paying $20 million up front to secure U.S. development and commercialization rights to Durect’s non-opioid post-surgical analgesic, Posimer® (SABER®-Bupivacaine). The drug, which...

DURECT Corporation to Participate in Upcoming Healthcare Conferences

CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo:  http://ph...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic de...

DURECT Corporation

More Information about "Durect" on BioPortfolio

We have published hundreds of Durect news stories on BioPortfolio along with dozens of Durect Clinical Trials and PubMed Articles about Durect for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Durect Companies in our database. You can also find out about relevant Durect Drugs and Medications on this site too.

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Corporate Database Quicklinks

Searches Linking to this Company Record